NewsRx

Search our medical news database

Parkinson Disease

Epilepsy drug improves tremors, involuntary movements in Parkinson patients

Published in Law and Health Weekly, January 27th, 2007

A drug used to treat epilepsy has been found to significantly improve tremors, motor fluctuations, and other involuntary movements, or dyskinesias, in patients with Parkinson disease, according to a study published in Neurology, the scientific journal of the American Academy of Neurology.

The three-month, multi-center study in Japan involved 279 Parkinson disease patients who weren't responding well to the commonly used drug, levodopa, to manage their symptoms. The patients were divided into groups that took 25, 50 or 100 mg a day of the drug zonisamide or placebo.

Researchers found at least 30% of patients taking zonisamide experienced a more...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook